Skip to main content
Equibles
VXRT logo

VXRT · Vaxart, Inc.

Track VXRT — free

Use VXRT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VXRT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.32 +0.00 (+0.00%) At close · Jul 8
Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“In the second quarter of 2026, management concluded that our cash, cash equivalents and investments are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our financial statements, and these conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 5, 2026
Market Cap
$126.27M
Shares
243.70M
Volume · Jul 8 11.57M Avg daily vol (3M) 4.77M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.32 Open$0.30 Day$0.30–0.34 52W close$0.31–0.99 Avg vol 30d8.0M Short int2.5M · 1.0% of shares · 3.9d Short vol36% Last earningsNov 5, 2026 DataJan 2020–Jul 2025 Filing10-Q · Nov 5

Up next

Next earnings call
Mar 11, 2027 Est · unconfirmed · in 17 wks
Q4 2025 earnings call transcript
call held Mar 12, 2026
Play latest call

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash Shortfall Raises Going-Concern Doubt

Vaxart reported $65.5 million in cash, cash equivalents and short-term investments as of September 30, 2026, saying they would not fund at least 12 months of operations and raising substantial doubt about its going concern.

Revenue $10.62M ▼ 85.3% Net loss $17.69M
Read from the first part of this long document
4 source passages
Aviragen changed its name to Vaxart, Inc. (together with its subsidiaries, the “Company” or “Vaxart”) and Private Vaxart changed its name to Vaxart Biosciences, Inc. As of September 30, 2026, the Company had cash, cash equivalents and short-term investments of $65.5 million. The Company’s cash, cash equivalents and investments are not sufficient to fund the Company’s planned operations for at least the period of 12 months from the date the unaudited condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of the issuance of these unaudited condensed consolidated financial statements. Open the document at this passage
Nov 5
Current report 8-K
COVID-19 trial data expected by mid-year 2027

Vaxart expects COVID-19 trial efficacy and safety data from 400 participants and approximately 5,000 participants by mid-year 2027. Third-quarter 2026 revenue was $10.6 million, and net loss was $17.7 million.

Financial results
4 source passages
COVID-19 Program Update The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, by mid-year 2027. Revenue for the third quarter of 2026 was $10.6 million, compared to $72.4 million for the third quarter of 2025. Vaxart reported a net loss of $17.7 million for the third quarter of 2026, compared to a net loss of $8.1 million for the third quarter of 2025. Open the document at this passage
Oct 19
Current report 8-K Events of Oct 16
Director or officer change, or executive pay, Regulation FD disclosure

Vaxart appointed retired Navy Vice Admiral Raquel C. Bono, M.D., to its Board of Directors effective October 16, 2026, pursuant to a July 2026 stockholder cooperation agreement, where she will chair the Stockholder Engagement Committee.

Sep 14
Current report 8-K Events of Sep 3
Other events AI summary on its way
Aug 25
Current report 8-K Events of Aug 21
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$181.27M
Trailing 12 months
Net income (TTM)
$29.04M
Trailing 12 months
Revenue growth YoY
-85.3%
Year over year
Operating margin
16.6%
Trailing 12 months
P / E (TTM)
4.3
Trailing earnings · reciprocal yield 23.0%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.3%
Year over year · more shares
Price change (1Y)
-48.4%
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲368% $15.19M −$11.98M '24 Q4* ▲857.2% $20.88M −$15.59M '25 Q1 ▲520.7% $39.73M −$14.99M '25 Q2 ▲1367.9% $72.41M −$8.14M '25 Q3 ▲586.5% $104.24M $55.05M '25 Q4* ▲87.9% $39.23M $5.18M '26 Q1 ▼31.6% $27.18M −$13.49M '26 Q2 LATEST ▼85.3% $10.62M −$17.69M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −46%
below
Price vs 50-day avg −31%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −56%
trailing
YTD return −52%
this year
Relative strength −62%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
6 of 4 funds reported for Sep 30 · net -19.4K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.01% of shares out · ▼ -4.4% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
4 holders — near 3-yr low, contrarian setup
Fundamentals
Excellent
Revenue growth +727%
Y/Y
EPS growth +121%
Y/Y
Free cash flow $7.6M
Quant / Vol
risk profile
Very High
Volatility 106%
annualized · 1-yr
Max drawdown −69%
past year
ATR 19.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−46% Bearish
Price vs 50-day avg
−31% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
6 of 4 funds reported for Sep 30 · net -19.4K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.01% of shares out · ▼ -4.4% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
4 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $1
vs 200-day avg -46% vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and short-term investments $64M as of June 30, 2026 —
Total amount of authorized funding for the complete study $344.8M Following the contract modification —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VXRT
Vaxart, Inc.
this stock
$126.27M — +726.7% — 1.0%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
5
% held
0.0%
Reported
6 of 4
Top holder
LVM CAPITAL MANAGEMENT LT…
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Falling
Shares short
2.5M
Days to cover
3.9d
Change
-113.0K sh
View
Short Volume
Short vol %
36%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
37.7K
Value
$20.7K
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 7, 2025
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$237.3M
Net income (FY)
$16.3M
EPS diluted
$0.07
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
44

Vaxart reported $65.5 million in cash, cash equivalents and short-term investments as of September 30, 2026, saying they would not fund at least 12 months of operations and raising substantial doubt about its going concern.

View
Proposed Sales
Value
$14.4K
Shares
40.0K
Filed
Dec 8, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
Vaxart to Host Stockholder Firesi…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
VXRT -28.9% -22.0% -55.6% -28.9% -51.5%
SPY +0.4% +3.5% +6.7% +0.4% +5.9%
vs SPY -29.3% -25.5% -62.3% -29.3% -57.4%
Key facts CIK 72444 CUSIP 92243A200 13F (30d) 17 filings 6 filers Visit website Investor relations